First-Ever Patent for Optimizing Human Healthspan

First-Ever Patent for Optimizing Human Healthspan

Los Angeles, Calif.July 31, 2018—On July 10, L-Nutra, Inc. became the first company to market a product that has been granted a patent by the United States Patent and Trademark Office (USPTO) for optimizing human healthspan, the length of time that a person is healthy. This is the first patented protocol to address health and wellness prior to the onset of disease. The patent is for the Fasting Mimicking Diet® (FMD®), discovered and clinically tested by the laboratory of Valter Longo and Keck Hospital at the University of Southern California (USC).

Fasting has always been part of human history; but recently, humans have become accustomed to eating multiple times a day, every day, causing a worldwide obesity epidemic. Over 70% of Americans are overweight or obese. Carrying excess fat accelerates the aging process and can lead to the early onset of disease. Fasting is gaining popularity, and there are many different types from the intermittent fast to prolonged fasting (3 or more days on a fast).  Prolonged fasts in particular are not only very difficult to comply with, but could pose health challenges and side effects if done outside of a specialized clinic. FMD protocols allow people to nourish their body with food while keeping the body in “fasting mode.” The current embodiment of the patent is ProLon®, a five-day FMD designed to minimize side effects and hunger thus making periodic fasting easy, effective, and safe.

The patent distinguishes the Fasting Mimicking Diet from other diets because it doesn’t require you to change the way you eat outside of the 5 days of the program.  It also provides the benefits of weight loss while maintaining lean body mass when completed once a month over 3 consecutive months. This is critical because prolonged fasts usually lead to lean body mass loss. The FMD positively stresses the body to induce major cellular benefits such as autophagy (awarded the 2016 Nobel Prize in Medicine). This regeneration and reset of the body could support healthier aging by helping maintain body weight and improving physical and mental performance in a way that takes advantage of natural human evolution, tradition, and cutting-edge science.

“This is a milestone achievement for public health, and L-Nutra is proud to be the first to market a product developed, tested, positioned, sold, and now patented for optimizing longevity and healthspan,” says Joseph Antoun MD, CEO of L-Nutra. “L-Nutra’s vision is to disrupt the current ‘sickcare’ model of medicine and to advance the concept of healthy and youthful longevity.”

The Fasting Mimicking Diet is one of few nutri-technologies that has undergone extensive scientific research and clinical trials at major universities across the world. Last year, a landmark human trial published in Science Translational Medicine demonstrated the benefits of ProLon® including weight loss, healthy aging, metabolic health, and more.

“At L-Nutra, we believe that by understanding and respecting nature, tradition, and science, we can promote remarkable self repair and reset mechanisms in the human body,” adds Dr. Antoun. L-Nutra’s plans include ongoing university studies to develop additional types of Fasting Mimicking Diets for addressing specific conditions such as multiple sclerosis, diabetes, cancer, and Alzheimer’s. For more information, please visit L-Nutra.com.

About L-Nutra, Inc.

L-Nutra’s team of researchers and collaborators are leaders in the field of nutrition related to longevity and healthspan. L-Nutra has the exclusive rights from the University of Southern California to market ProLon® and other FMD®s, which mimic and enhance the effects of fasting, unleash the body’s natural ability to rejuvenate itself, and promote healthy longevity. These nutri-technologies are the result of decades of lab and clinical research to demonstrate safety and efficacy. For more information, please visit l-nutra.com  and prolonfmd.com.


Leave a comment

Please note, comments must be approved before they are published